JP2022536338A - Arsa遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法 - Google Patents

Arsa遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法 Download PDF

Info

Publication number
JP2022536338A
JP2022536338A JP2021573242A JP2021573242A JP2022536338A JP 2022536338 A JP2022536338 A JP 2022536338A JP 2021573242 A JP2021573242 A JP 2021573242A JP 2021573242 A JP2021573242 A JP 2021573242A JP 2022536338 A JP2022536338 A JP 2022536338A
Authority
JP
Japan
Prior art keywords
amino acid
seq
capsid protein
protein corresponding
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536338A5 (cg-RX-API-DMAC7.html
Inventor
ティア・バボヴァル・セント・マーティン
アルバート・バーンズ・シーモア
ヒラード・ルビン
Original Assignee
ホモロジー・メディシンズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホモロジー・メディシンズ・インコーポレイテッド filed Critical ホモロジー・メディシンズ・インコーポレイテッド
Publication of JP2022536338A publication Critical patent/JP2022536338A/ja
Publication of JP2022536338A5 publication Critical patent/JP2022536338A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021573242A 2019-06-10 2020-06-09 Arsa遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法 Pending JP2022536338A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962859539P 2019-06-10 2019-06-10
US62/859,539 2019-06-10
US201962866374P 2019-06-25 2019-06-25
US62/866,374 2019-06-25
US201962915523P 2019-10-15 2019-10-15
US62/915,523 2019-10-15
US202062960487P 2020-01-13 2020-01-13
US62/960,487 2020-01-13
US202062987858P 2020-03-10 2020-03-10
US62/987,858 2020-03-10
US202063010970P 2020-04-16 2020-04-16
US63/010,970 2020-04-16
PCT/US2020/036846 WO2020251954A1 (en) 2019-06-10 2020-06-09 Adeno-associated virus compositions for arsa gene transfer and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022536338A true JP2022536338A (ja) 2022-08-15
JP2022536338A5 JP2022536338A5 (cg-RX-API-DMAC7.html) 2023-06-05

Family

ID=73782242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573242A Pending JP2022536338A (ja) 2019-06-10 2020-06-09 Arsa遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法

Country Status (15)

Country Link
US (1) US20220204991A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980447A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022536338A (cg-RX-API-DMAC7.html)
KR (1) KR20220035107A (cg-RX-API-DMAC7.html)
CN (1) CN114502575A (cg-RX-API-DMAC7.html)
AU (1) AU2020292256B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024855A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142932A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003295A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016797A2 (cg-RX-API-DMAC7.html)
IL (1) IL288863A (cg-RX-API-DMAC7.html)
MX (1) MX2021015076A (cg-RX-API-DMAC7.html)
PE (1) PE20220233A1 (cg-RX-API-DMAC7.html)
TW (1) TW202112807A (cg-RX-API-DMAC7.html)
WO (1) WO2020251954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769577C1 (ru) * 2021-06-01 2022-04-04 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Препарат для лечения метахроматической лейкодистрофии и способ ее лечения
CN119213120A (zh) * 2022-05-16 2024-12-27 建新公司 治疗异染性脑白质营养不良的方法
MA71631A (fr) 2022-07-29 2025-05-30 Regeneron Pharmaceuticals, Inc. Particules virales reciblées vers le récepteur 1 de transferrine
WO2024036250A2 (en) * 2022-08-10 2024-02-15 Homology Medicines, Inc. Adeno-associated virus compositions for arsa gene transfer and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180021364A1 (en) * 2015-01-16 2018-01-25 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
US20180071373A1 (en) * 2015-05-15 2018-03-15 Regents Of The University Of Minnesota Adeno-associated virus for therapeutic delivery to central nervous system
US20180163227A1 (en) * 2010-04-30 2018-06-14 City Of Hope Recombinant adeno-associated vectors for targeted treatment
JP2018522546A (ja) * 2015-06-18 2018-08-16 ザ・ブロード・インスティテュート・インコーポレイテッド オフターゲット効果を低下させるcrispr酵素突然変異

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738326B2 (en) * 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
JP6836999B2 (ja) * 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California アデノ随伴ウイルス変異体及びその使用方法
WO2019152841A1 (en) * 2018-02-01 2019-08-08 Homology Medicines, Inc. Adeno-associated virus compositions for pah gene transfer and methods of use thereof
CA3129321A1 (en) * 2019-02-15 2020-08-20 Generation Bio Co. Modulation of rep protein activity in closed-ended dna (cedna) production
JP7715640B2 (ja) * 2019-05-03 2025-07-30 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異染性白質ジストロフィーの治療に有用な組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180163227A1 (en) * 2010-04-30 2018-06-14 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US20180021364A1 (en) * 2015-01-16 2018-01-25 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
US20180071373A1 (en) * 2015-05-15 2018-03-15 Regents Of The University Of Minnesota Adeno-associated virus for therapeutic delivery to central nervous system
JP2018522546A (ja) * 2015-06-18 2018-08-16 ザ・ブロード・インスティテュート・インコーポレイテッド オフターゲット効果を低下させるcrispr酵素突然変異

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KURAI, T., ET AL.: ""AAV1 mediated co-expression of formylglycine-generating enzyme and arylsulfatase A efficiently corr", MOLECULAR THERAPY, vol. 15, no. 1, JPN6024018398, January 2007 (2007-01-01), pages 38 - 43, ISSN: 0005484297 *
YAMAZAKI, Y., ET AL.: ""Targeted gene transfer into ependymal cells through intraventricular injection of AAV1 vector and l", SCIENTIFIC REPORTS, vol. 4, JPN6024018397, 1 July 2014 (2014-07-01), pages 1 - 7, ISSN: 0005484296 *

Also Published As

Publication number Publication date
AU2020292256A1 (en) 2022-01-06
IL288863A (en) 2022-02-01
US20220204991A1 (en) 2022-06-30
BR112021024855A2 (pt) 2022-05-03
TW202112807A (zh) 2021-04-01
EP3980447A1 (en) 2022-04-13
KR20220035107A (ko) 2022-03-21
CN114502575A (zh) 2022-05-13
PE20220233A1 (es) 2022-02-07
CA3142932A1 (en) 2020-12-17
MX2021015076A (es) 2022-06-02
CO2021016797A2 (es) 2022-01-17
AU2020292256B2 (en) 2023-01-19
WO2020251954A1 (en) 2020-12-17
EP3980447A4 (en) 2023-07-26
CL2021003295A1 (es) 2022-09-23

Similar Documents

Publication Publication Date Title
JP7433360B2 (ja) Pah遺伝子移入のためのアデノ随伴ウイルス組成物及びそれらの使用方法
AU2016341428B2 (en) Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
CN111902539B (zh) 杂合调控元件
JP2022088645A (ja) 高ビリルビン血症の処置
RU2725813C2 (ru) Векторы, содержащие спейсерные/филлер полинуклеотидные последовательности, и способы их применения
JP2020050660A (ja) 脊髄疾患の遺伝子療法
JP7860958B2 (ja) メチルcpg結合タンパク質2(mecp2)プロモータ配列を含む核酸構築体を用いた遺伝子治療
US20220204991A1 (en) Adeno-Associated Virus Compositions for ARSA Gene Transfer and Methods of Use Thereof
US20130317091A1 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
KR20230038503A (ko) 샤르코-마리-투스 질환의 치료에 유용한 조성물
JP7616668B2 (ja) Ube3a遺伝子および発現カセットならびにそれらの使用
US12203094B2 (en) Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
CN118119710A (zh) 用于治疗脊髓性肌萎缩的重组腺相关病毒载体
HUE026796T2 (en) Cholesterol 24-hydrolase expression vector for the treatment of huntington's disease
CN117897492A (zh) 用于肌肉和cns中的基因表达的杂合启动子
KR20230112672A (ko) 신경변성 질환을 위한 유전자 요법
JP2026509301A (ja) 遺伝子治療
US20210361778A1 (en) Adeno-associated virus compositions for ids gene transfer and methods of use thereof
CN117377771A (zh) 载体系统
WO2024036250A2 (en) Adeno-associated virus compositions for arsa gene transfer and methods of use thereof
WO2023034966A1 (en) Compositions and methods of using the same for treating disorders associated with thymosin βeta 4
NZ753155B2 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
NZ713958B2 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
NZ713958A (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241216